相关实验视频
Updated: Jul 1, 2025
05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
4.6K
与 HER2 向癌症治疗相关的晚期心脏毒性
Isabelle Senechal1,2, Maria Sol Andres3, Jieli Tong3
1Cardio-Oncology Service, Royal Brompton Hospital, Guy's and St. Thomas' NHS Foundation Trust, London, UK. isabelle.senechal-dumais.1@ulaval.ca.
Cardio-oncology (London, England)
|March 8, 2024
概括
晚期发作的心脏功能障碍可能发生在多年抗HER2治疗转移性癌症后. 持续的心血管监测对于接受长期HER2向治疗的患者至关重要.
科学领域:
- 心脏病学 心脏病学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 长期的抗HER2治疗越来越多地用于转移的HER2+癌症.
- 关于晚期癌症治疗相关心脏功能障碍 (CTRCD) 的发生率和危险因素的数据有限.
- 了解晚期发病的CTRCD对于治疗长期抗HER2治疗方案的患者的管理至关重要.
研究的目的:
- 在接受长期抗HER2治疗的患者中调查晚发性CTRCD的发生率和特征.
- 确定与延迟心脏功能障碍相关的潜在风险因素和临床结果.
- 强调在这种患者群体中持续进行心血管监测的重要性.
主要方法:
- 对一组被转诊到心脏瘤服务的患者进行了回顾性分析.
- 纳入标准:转移的HER2+癌症,至少五年持续的抗HER2治疗,以及CTRCD的发展.
- 数据收集包括心脏功能参数 (LVEF,GLS) 和治疗史.
主要成果:
- 17名患者在接受抗HER2疗法的中位数为6.5年后发生了CTRCD.
- 最低的LVEF中位数为49%,GLS为-15.4%.
- 大多数患者继续使用抗HER2治疗,接受心力衰竭治疗,随访时LVEF正常化.
结论:
- 与癌症治疗相关的心脏功能障碍可能在开始抗HER2治疗后的几年内表现出来.
- 抗HER2治疗通常可以继续或重新启动,并对CTRCD进行医疗管理.
- 对于接受长期抗HER2治疗的患者,持续的心血管监测至关重要.
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:26Heart Failure Drugs: Inotropic Agents
586
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
586
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
429
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
429
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K